Lupin Limited launched Ancobon Capsules’ for cryptococcosis treatment market

 

The growing prevalence of cryptococcus disease is escalating the growth of the cryptococcosis treatment market. The Centers for Disease Control and Prevention (CDC) states that around 1 million cryptococcosis cases arise throughout the globe, and it is anticipated that annually, the number of deaths associated with cryptococcosis is around 650,000. Most of the cases are reported among patients with complex HIV disease. Moreover, rising count of people being contaminated by the disease such as AIDS is propelling the growth of the cryptococcosis treatment. India has the third-largest HIV epidemic in the world. In 2017, HIV prevalence among adults (aged 15-49) was an estimated 0.2%. HIV prevalence is higher among men than women, with 0.25% of men and 0.19% of women living with HIV as of 2017.

In January 2018, Lupin Limited, an Indian pharmaceutical company, launched a generic version of Valeant Pharmaceutical International Inc.’s ‘Ancobon Capsules’. These capsules are indicated for infections caused by Cryptococcus

In September 2017, CHAI’s HIV Access Program launched an online HIV New Product Introduction Toolkit and an accompanying HIV New Product Introduction Guide to provide partners and Ministries of Health with the tools and resources needed to introduce and scale up new optimal antiretrovirals (ARV) in-country

In March 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body

North America is expected to dominate the global cryptococcosis treatment market and this can be attributed to the growing FDA approval for the launch of new products. For instance, in February 2019, Amplyx Pharmaceuticals, a U.S.-based pharmaceutical company, received orphan drug designation for APX001 from the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development. This drug will be used for the treatment of cryptococcosis.

Cryptococcosis, also known as "scooting to death," is an infectious disease with an agent that causes infection by encapsulation of naturally occurring yeast in the lungs, and sometimes in other body tissues (such as the genital area). It is most commonly associated with the inhalation of contaminated soil where the encapsulated yeast cells produce aerosol particles (or "crypts") that become airborne and are inhaled. The disease has an incubation period of two to six weeks and is most common after someone has had contact with contaminated soil during camping or traveling.